Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3568067 | 0.91 | GSK3B (0.41) | GSK3BCYP1A2CYP2D6CYP3A4CYP2C19 | |
| SCHEMBL3576425 | 0.89 | GSK3B (0.45) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL3575938 | 0.89 | GSK3B (0.40) | GSK3BCYP1A2CYP2D6CYP3A4 | |
| SCHEMBL6648271 | 0.86 | GSK3B (0.44) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL3571557 | 0.86 | GSK3B (0.45) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL3573673 | 0.83 | GSK3B (0.46) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL3563256 | 0.81 | GSK3B (0.39) | GSK3BCYP1A2CYP2D6CYP3A4 | |
| SCHEMBL3565488 | 0.80 | GSK3B (0.49) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL3572812 | 0.80 | GSK3B (0.45) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL3573772 | 0.80 | GSK3B (0.46) | GSK3BCYP1A2CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430056-A1 | SUBSTITUTED 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES FOR NEURODEGENERATIVE DISORDERS | Sanofi-Aventis (FR) | 2004-06-23 | — | — | EP | claimed |
| WO-2003027115-A1 | SUBSTITUTED 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES FOR NEURODEGENERATIVE DISORDERS | SANOFI-SYNTHELABO (FR) | 2003-04-03 | — | — | WO | claimed |